North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
Publication|Articles|October 25, 2024
- October 2024
- Volume 30
- Issue 11
- Pages: SP870-SP873
Beyond McKesson and Florida Cancer Specialists, Deals Are Reshaping Community Oncology
Author(s)Mary Caffrey
Advertisement
Advertisement
When word got out on August 26, 2024, that McKesson Corporation had agreed to pay $2.49 billion for a controlling interest in a unit of Florida Cancer Specialists & Research Institute (FCS),1 the news was jolting but not unexpected. There had been reports2 and speculation for more than a year on who would be the winning suitor for FCS, with its 100 sites and a huge footprint in both the Florida market and the research community.
Related to this article
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
Advertisement
Advertisement